Clinical Trials Logo

Filter by:
NCT ID: NCT01636076 Completed - COPD Clinical Trials

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 2012
Phase: Phase 2
Study type: Interventional

To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD

NCT ID: NCT01634113 Completed - Asthma Clinical Trials

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with persistent asthma on top of inhaled corticosteroid (ICS) treatment.

NCT ID: NCT01633398 Completed - Heart Failure Clinical Trials

ASIAN HF Registry, A Prospective Observational Study

ASIANHF
Start date: September 2012
Phase:
Study type: Observational

The ASIAN HF Registry is the first prospective multinational Asian registry of patients with symptomatic HF (stage C) including both HFrEF (ejection fraction <40%) and HFpEF (ejection fraction ≥50%), with the broad purpose of determining the mortality (incidence) burden of HF in Asian patients, and more specifically to define the burden and risk factors of Sudden Cardiac Deaths (SCD), as well as the sociocultural barriers to preventive device therapy. The study further aim to study the genetic variants associated with HFrEF versus HFpEF in our large Asian cohort. This proposed registry is expected to advance fundamental understanding of the burden and predictors of preventable death among Asian patients with HF. The knowledge gained will be critical for guiding resource allocation and planning preventive strategies to address the unmet and growing clinical needs of patients with cardiovascular disease in Asia.

NCT ID: NCT01631838 Completed - Metabolic Syndrome Clinical Trials

Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome

Start date: May 2012
Phase: N/A
Study type: Interventional

The objective of this study is to address the anti-thrombotic effects of tocotrienols supplementation via modulation of platelet activation, thrombotic markers, inflammatory markers and endothelial function. It is hypothesized that 2 weeks supplementation of tocotrienols will be able to suppress platelet aggregation in subjects with metabolic syndrome.

NCT ID: NCT01626456 Completed - Schizophrenia Clinical Trials

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Start date: June 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.

NCT ID: NCT01626430 Completed - Metabolic Syndrome Clinical Trials

Acute Effects of Tocotrienols on Insulin Sensitivity and Metabolic Risk Markers in Individuals at Risk for Metabolic Syndrome

Start date: January 2012
Phase: N/A
Study type: Interventional

Objectives: To compare the acute effects of gamma delta rich tocotrienol fractions (gd-TRF) on insulin sensitivity, metabolic risk markers and postprandial lipemia in individuals at risk for metabolic syndrome. Hypothesis: Gamma delta-rich TRF will improve insulin sensitivity, metabolic risk markers and postprandial lipemia in individuals at risk for metabolic syndrome.

NCT ID: NCT01618695 Completed - Clinical trials for Partial-onset Seizures

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Start date: May 15, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures

NCT ID: NCT01614912 Completed - Schizophrenia Clinical Trials

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Start date: August 2012
Phase: Phase 3
Study type: Interventional

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

NCT ID: NCT01614899 Completed - Schizophrenia Clinical Trials

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Start date: July 2, 2012
Phase: Phase 3
Study type: Interventional

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

NCT ID: NCT01610414 Completed - Herpes Zoster Clinical Trials

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Start date: July 13, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in reducing the risk of developing HZ in this population.